NBPF7 inhibitors are chemical compounds that specifically target and inhibit the activity of the NBPF7 protein, a member of the neuroblastoma breakpoint family of proteins (NBPF). This family of proteins is characterized by its involvement in a variety of cellular processes, primarily related to cell division and differentiation. NBPF7 is part of a larger set of genes that are known for their role in the evolution and complexity of human-specific neurodevelopmental pathways. These inhibitors work by interfering with the typical molecular interactions involving NBPF7, thereby regulating its normal function in the cell. The precise mechanisms of inhibition can vary depending on the chemical nature of the inhibitors, with some compounds acting directly on the active site of the NBPF7 protein and others modulating its activity through allosteric binding.
The development and characterization of NBPF7 inhibitors are important for understanding the broader function of NBPF7 in cellular processes. The study of these inhibitors allows for the exploration of the structural and functional dynamics of the NBPF7 protein, particularly how it interacts with other proteins and signaling pathways. This can also provide insights into the protein's involvement in various cellular phenomena such as genomic stability and protein expression regulation. As research progresses, NBPF7 inhibitors serve as valuable tools for probing the role of NBPF7 in biological systems, shedding light on its role in cell division, growth regulation, and possibly evolutionary development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin can affect cell growth and proliferation, potentially influencing NBPF7 activity in cancer cells. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
Temozolomide's alkylating properties could indirectly affect NBPF7 through DNA damage response pathways. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
A drug that causes DNA damage, possibly influencing NBPF7 activity indirectly in cancer pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
An MEK inhibitor that might indirectly influence NBPF7 by altering cell signaling pathways in cancer. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Similar to Rapamycin, affects mTOR pathways, possibly influencing NBPF7 indirectly in cancer cells. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
A multi-kinase inhibitor, could indirectly affect NBPF7 by modulating various signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, might impact NBPF7 indirectly through protein degradation pathways. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
An EGFR inhibitor, potentially influencing NBPF7 indirectly by affecting growth factor signaling. | ||||||